Abstract. Increased membrane permeability and myofibrillar protein breakdown are established features of cancer cachexia. Proteins released from cachectic muscle may be excreted in urine to act as biomarkers of the cachectic process. Onedimensional SDS polyacrylamide gel electrophoresis followed by matrix-assisted laser desorption/ionisation or liquid chromatography tandem mass spectrometry was used to compare the protein content of urine from cachectic (>10% weight loss) (n=8) and weight-stable (n=8) gastro-oesophageal cancer patients and healthy controls (n=8). Plasma creatine kinase concentration was used as a marker of gross muscle breakdown. The number of protein species identified in cachectic samples (median 42; range 28-61; total 199) was greater than that identified in weight-stable cancer (median 15; range 9-28; total 79) and control samples (median 12.5; range 5-18; total 49) (P<0.001). Many of the proteins identified have not been reported previously in the urine of cancer patients. Proteins identified specifically in cachectic samples included muscle (myosin species), cytoskeletal (·-spectrin; nischarin) and microtubule-associated proteins (microtubule-actin crosslinking factor; microtubule-associated protein-1B; bullous pemphigoid antigen 1), whereas immunoglobulin κ-light chain and zinc ·-2 glycoprotein appeared to represent markers of cancer. The presence of myosin in urine (without an increase in plasma creatine kinase) is consistent with a specific loss of myosin as part of the cachectic process. Urinary proteomics using mass spectrometry can identify muscle-specific and non-muscle-specific candidate biomarkers of cancer cachexia.
Introduction
Cancer cachexia is a condition of severe malnutrition and negative nitrogen balance that occurs in up to one half of all cancer patients and which results in an increase in patient morbidity and mortality (1) . Once cachexia is clinically evident (e.g. by deterioration of nutritional status or muscle strength), the syndrome is more difficult to reverse (2) . Thus, a systematic approach to the management of cachexia requires early identification of patients at risk and institution of prophylactic measures to attenuate its progression. However, there are currently no agreed early biomarkers (clinical or biochemical).
Systemic inflammation is considered to be one of the key mechanisms leading to cancer cachexia (3) . Pro-inflammatory cytokines not only induce breakdown of skeletal muscle protein, but have more general effects, including an increase in capillary permeability and activation of the hepatic acute phase response (4) (5) (6) . Thus, systemic inflammation is often evidenced by an increase in plasma concentrations of positive acute phase reactants [e.g. C-reactive protein (CRP) >10 mg/l]. However, despite the importance of pro-inflammatory cytokines in cachexia, plasma concentrations tend to fluctuate, thereby reducing their potential as effective biomarkers.
During the catabolic response in skeletal muscle, release of myofilaments from the sarcomere by calcium/calpaindependent pathways is an early and perhaps rate-limiting, step (7) . Activation of the ubiquitin-proteasome pathway (UPP) then degrades released myofibrillar proteins (3) . In murine tumour models, cancer cachexia involves the selective reduction of myosin heavy chain (MyHC) protein expression within skeletal muscle (8) . This reduction in MyHC levels is associated with increased activity of the UPP, suggesting that cachexia is the result of targeted depletion of specific myofibrillar proteins. Studies in cytokine-dependent animal tumour models have also identified specific changes in skeletal muscle membrane structure and function during cachexia (9) . In particular, the dystrophin glycoprotein complex appears dysregulated and the sarcolemma becomes permeable to vital dyes. However, the severity of membrane damage would appear, at first glance, to be insufficient to cause a free permeation of intracellular proteins, particularly as circulating levels of creatine kinase (CK), a marker of muscle damage, are not elevated (9, 10) .
The multifactorial catabolic and inflammatory mechanisms at work in cancer cachexia result in an increase in circulating proteins, leading to significant proteinuria and urinary nitrogen loss (2) . Such proteinuria has been shown to be associated with worsened patient prognosis (11) . However, the exact identity of protein species within the urine has not been elucidated. We hypothesized that the identification of proteins within the systemic compartment of cachectic patients may identify proteins that have been degraded selectively. The identification of proteins within patient plasma (as a representative matrix of the systemic compartment) is highly complex due to the multiplicity of species involved in non-cachectic processes found therein (12) . However, mass spectrometry (MS) has been successful at species identification within urine (13) . Thus, in a preliminary attempt to identify urinary proteins that might be used in future biomarker studies to target patients for therapeutic intervention, we aimed to use MS to identify and compare the protein contents of urine from cachectic cancer patients, weight-stable cancer patients and healthy controls.
Materials and methods

Patients and controls.
Patients provided written, informed consent and the study was approved by the Lothian Research Ethics Committee. Patients with newly diagnosed gastrooesophageal (GO) adenocarcinoma or squamous cell carcinoma who were undergoing elective resection with curative intent were recruited for the study (n=16), prior to July 2008. GO cancer patients have a high incidence of weight loss (1) and were therefore chosen as a representative group of patients who develop cachexia. Cancer patients were separated into two groups: those who had lost >10% of premorbid body weight and were therefore considered to be cachectic (CC group) (n=8), and those who had lost minimal weight and were thus considered to be weight-stable (WS group) (n=8). Urinary samples were also collected from healthy, weight-stable volunteers who served as controls (HC group) (n=8). Individuals with known previous renal failure were excluded.
Anthropometry. Height was measured using a wall-mounted stadiometer with the patient standing erect without shoes. Patients were weighed on spring balance scales without shoes and wearing light clothing. Pre-illness stable weight was selfreported by patients. Mid-arm circumference (MAC) was measured at the mid-point between the acromion and olecranon processes. Triceps skinfold thickness (TSF) was measured with Harpenden skin callipers (Holtain, Crymych, UK). Mid-arm muscle circumference (MAMC) was calculated according to the formula: MAMC = MAC-[ x TSF]. Karnofsky performance score (KPS) was documented by the recruiting physician.
Plasma tests. Plasma creatinine concentration was measured using a kinetic Jaffe technique (Olympus AU2700 analyzer: Olympus UK Ltd, Watford, UK; normal defined as <120 μmol/l). Plasma CK concentration was measured using a CK-NAC (IFCC) technique (Olympus AU2700 analyzer; normal defined as <170 U/l in males and <135 U/l in females). Within and between-run CVs were <2.0% at all concentrations for both tests. Plasma CRP concentration was measured using quantitative immunoturbidimetry (Olympus AU2700 analyzer; CRP>10 mg/l considered evidence of a positive acute phase response) with CVs of 3.4% at concentrations <15 mg/l and 1.6% at 80 mg/l.
Urinary sampling and protein precipitation. Morning urine samples were taken and stored at -20˚C until analysis. First urine samples of the day were not used in order to avoid urine which may have remained in the bladder overnight. Following centrifugation to remove debris, proteins were precipitated from 20 ml urine by incubation at -20˚C for 2 h with 40 ml cold acetone containing 20 mM dithiothreitol (DTT). Samples were centrifuged and the protein pellet was re-dissolved in 3 ml PBS/3 ml rehydration buffer (8 M urea, 2% CHAPS, 20 mM DTT). A 200 μl aliquot was centrifuged and the supernatant assayed for protein concentration using the Bradford technique (Bio-Rad Protein Assay kit, USA) Absorbance was read at 630 nm (MRX II spectrophotometer, Dynex Technologies). A standard curve was created by diluting bovine-Á-globulin protein standard with PBS and rehydration buffer at a 1:1:1 ratio.
1D SDS-PAGE gel electrophoresis. Preliminary unpublished study with 2D gels of urine demonstrated a low level of complexity compared to previous experience with plasma, serum and saliva; thus, 1D SDS-PAGE was used for initial separation (NuPAGE Novex 4-12% Bis-Tris gradient gels, Invitrogen). In order to avoid potential 'masking' of normal urinary proteins by novel species that may be highly prevalent in WS/CC urine, equal volumes (rather than equal amounts) of precipitated protein supernatant were loaded onto gels. Thirteen microliters of protein sample were prepared with 5 μl of 4X SDS sample buffer and 2 μl of 10X reducing agent. Gels were loaded with low and high molecular weight markers (GE Healthcare UK Ltd, Little Chalfont, UK) and stained with GelCode Blue (Pierce). Using a clean scalpel, bands were excised in an identical fashion from each gel lane in 7 separate blocks (Fig. 1) .
In-gel tryptic digestion. Gel blocks were incubated three times in 200 mM NH 4 HCO 3 in 50% acetonitrile (ACN) at 30˚C for 30 min. Each block was then incubated in 20 mM DTT/200 mM NH 4 HCO 3 in 50% ACN at 30˚C for 1 h to reduce the protein, followed by three washes in 200 mM NH 4 HCO 3 in 50% ACN. Cysteines were alkylated by incubation in 50 mM iodoacetamide/200 mM NH 4 HCO 3 in 50% ACN at room temp for 20 min in the dark, followed by 3 further washes. Gel blocks were cut into pieces and incubated with 100% ACN until white. Gel pieces were then air-dried before incubation with 0.5 μg trypsin (Promega, UK) in 50 mM NH 4 HCO 3 for 16 h.
MS analysis.
Tryptic digests were sonicated for 10 min. Samples were zip-tipped (C18 Zip-Tip, Millipore) to reduce salt contamination. For MALDI-TOF MS analysis, 0.5 μl aliquots of the tryptic digests were mixed with 0.5 μl of 10 mg/ ml CHCA matrix, and analysed using a Voyager DE-STR MALDI-TOF mass spectrometer (Applied Biosystems). Processed spectra were searched against the Swissprot and National Center for Biotechnology Infomation (NCBI) nonredundant databases using Protein Prospector MSFit and Mascot PMF (Matrix Science). Search parameters included a maximum of 1 missed cleavage per peptide and a mass tolerance of 100 ppm. Proteins with a significant MOWSE score (P<0.05) are reported. For LC tandem MS analysis, tryptic digests from gel blocks were pooled into two groups by molecular weight: MW ≤30 kDa and MW >30 kDa. Pooled samples were spun through a 0.22 μm filter (Millipore). Each pooled sample (100 μl) was loaded onto a PepMap C18 column (3 μm particle size, 75 μm x 15 cm) on a Famos/Swichos/Ultimate high performance liquid chromatography (HPLC) system (Dionex, UK) at a flow rate of 200 nl/min. The column was equilibrated with solvent A (0.1% formic acid) and eluted with a linear gradient from 0 to 70% solvent B (0.1% formic acid in 100% acetonitrile) over 45 min. Flow was controlled by Chromeleon software and interfaced to the LCQ deca MS (Thermo Scientific) with a PicoTip (FS-360-20-10-N-20-C12 DOM, New Objective, UK). Output was monitored at 214 nm. Data-dependent acquisition was controlled by Xcalibur software and database searching was achieved using TurboSequest software and Mascot. Redundancy was avoided within the protein counts by identifying the gene of origin of hypothetical and KIAA proteins wherever possible.
Statistical analysis. All statistical analyses were performed using Statistical Package for Social Services version 13.0 (SPSS 13.0; Chicago, IL, USA). Concentrations of the precipitated protein supernatants were used to derive protein concentrations of the initial urine samples in mg/l. Differences between distribution functions of data for the 3 patient groups was determined by Kruskal-Wallis (KW) test. Subsequent analysis to determine differences between any 2 groups was determined by Mann-Whitney U test (MW) and Fisher's exact test (FE). All quoted P-values are two-sided. Asymptotic P-values are quoted for KW test whereas two-sided exact P-values are quoted for MW test. Statistical significance was set at P<0.05 level.
Results
Patient demographics. Tumour site, histology and stage of disease did not differ between the WS and CC groups ( Table I ). The HC group was younger than both the WS group (P=0.001) and CC group (P=0.002) (Table II) Table I . Tumour details of the recruited gastro-oesophageal cancer patients (n=16). 
and HC groups which had not lost weight (P<0.001). Other nutritional parameters (BMI, mid-arm circumference, mid-arm muscle circumference) were also reduced in the CC group compared with the WS group, consistent with a specific loss of skeletal muscle mass in the CC group. The WS group exhibited an elevated BMI compared with the HC group, reflecting the role of obesity in the pathogenesis of GO adenocarcinoma.
Plasma levels. Plasma creatinine was elevated in one patient in the WS group suggesting mild renal impairment, but there was no overall difference between the WS and CC groups (P=0.234). Six (37.5%) cancer patients exhibited evidence of an acute phase response (plasma CRP >10 mg/l), but there was no difference in CRP between the WS and CC groups (P=0.613). Plasma CK was not elevated in any of the cancer patients and did not differ between the WS and CC groups (P=0.083).
Cachectic cancer urine contains more protein species than weight stable cancer and control urine. There was no significant difference in the urinary protein concentration of the three patient groups (P=0.149) (Table II) . Thus, the finite amounts of protein loaded onto gels were comparable statistically. Using both MS approaches, the number of proteins identified in each CC urine sample (median 42, range 26-61) was greater than that identified in each WS sample (median 15; range 9-28) and HC sample (median 12.5; range 5-18) (P<0.001) (Table III) . Furthermore, the total number of different protein species identified in all samples of the CC group combined (n=199) was higher than that identified in the WS (n=79) and HC (n=49) groups (Table III) . There was no difference between the total number of proteins identified in the WS group compared with the HC group (P=0.234). In all 3 groups, the number of proteins identified by MALDI-TOF MS was higher than that identified by LC-MS/MS.
Candidate biomarkers of cachexia. The distribution of gel bands did not differ observably between the 3 patient groups (Fig. 1) . Thirty-five protein species were identified that appeared in at least 3 urine samples within any patient group of 8 (i.e. at least 37.5%). Of these 35 species, 21 were not specific to the CC group. These non-cachexia-specific protein species included common urinary proteins such as albumin, cytokeratins 1 and 10 and uromodulin, plus many proteins not previously reported in the urine of cancer patients (Table IV) . Immunoglobulin (Ig) κ-light chain was identified in 6 (75%) CC samples and 4 (50%) WS samples compared with 1 (12.5%) HC sample (CC vs. HC P=0.041), whereas zinc ·-2 glycoprotein (ZAG) (either precursor chains A-D or the whole molecule) was identified in 5 (62.5%) CC samples and 5 (62.5%) WS samples compared with 1 (12.5%) HC sample. These two proteins may therefore represent markers of cancer or ill-health.
All of the CC samples exhibited at least one species of myosin, including sarcomeric myosin heavy chain 2 and myosins 3a, 4, 5a, 5c, 7a, 8, 9a, 9b, 10, 13 and 18b. In comparison, none of the WS samples expressed myosin species whereas only one (12.5%) HC sample expressed myosin 18b. Furthermore, all of the CC samples expressed Table II . Characteristics of healthy, weight-stable, non-cancer controls, the weight-stable cancer patients and the cancer cachexia patients (>10% weight loss).
- Tables V and VI. Retrospective analysis of 1D gels suggests that some markers (e.g. myosins and ·-spectrin) were excreted in complete or near-complete form, whereas other biomarkers (e.g. MACF1) appear to have been digested into smaller peptides prior to excretion.
Discussion
MS has been utilised successfully for the identification of urinary proteins (13), oligosaccharides (14) and nucleosides (15) . Furthermore, MALDI-MS has been employed in the detection of biomarkers in kidney disease (16), genitourinary tumours, including bladder (17) and prostate cancer (18) , and tumours outwith the genitourinary tract, including pancreatic (19) and colon cancer (20) . In this preliminary study, MS was used to demonstrate that urine from cachectic GO cancer patients contained significantly more protein species than urine from weight-stable GO cancer patients and healthy controls, in the absence of an elevated CK level. Cancer patients were older than healthy controls, but ages of the WS and CC groups were comparable, and thus age alone is unlikely to explain the different numbers of protein species between groups. MALDI-MS was capable of identifying more protein species than LC-MS/MS. Furthermore, all cachexia-specific protein species were detected exclusively by MALDI-MS. These results probably reflect the increased sensitivity of MALDI-MS, and the fact that, during LC-MS/MS analysis, highly abundant proteins will mask less abundant species (21) . Masking may have taken place during LC-MS/MS analysis within the present study as, for example, uromodulin was detected by LC-MS/MS in all members of the HC group, but was found in only 2 of the WS group and 1 of the CC group.
The protein species identified specifically in the cachectic urine samples could be considered to share a common structural function, and thus their urinary excretion might point to a prima facie deterioration in muscle structure during cachexia. The myofibrillar proteins detected in cachectic urine were predominantly myosin species. Titin and cytoplasmic actin 1 were found in individual cachectic patients but none of the other core myofibrillar proteins, such as troponin T and tropomyosin, were detected. Myosins can be subdivided into 18 different classes based on homologous myosin head domain sequences (22) . Conventional myosins, such as those found in muscle tissue, are composed of two myosin heavy-chain (MyHC) subunits, each associated with two light-chain subunits that bind at the neck region and play a regulatory role. Unconventional myosins, believed to function in intracellular motion and signal transduction (23), may contain one or two heavy chains, and associated light chains. The seven MyHC isoforms that predominate in mammalian skeletal muscles include two developmental isoforms (MyHCembryonic and MyHC-perinatal); three adult skeletal muscle isoforms (MyHC-IIa, MyHC-IIb, MyHC-IIx/d); and MyHC-ß/ slow, which represents the main MyHC component in slow, oxidative, type I skeletal muscle fibres and cardiac muscle (24) . This last isoform (specifically MyHC 7/cardiac muscle/ ß variant) was identified specifically in cachectic urine within the present study. At first glance, this result might appear contradictory to previous studies, which have predominantly found a reduction in type II fast fibres in cachectic muscle (9) . However, studies have also found slight reductions in type I MyHC within cachectic muscle (9) and switching of fibre-type from I to IIa in animal tumour models (25) .
The remaining four myosins (5c, 7a, 9a and 10) detected exclusively in cachectic patients were all unconventional myosins. Myosin 18b was detected in 3 cachectic patients, INTERNATIONAL JOURNAL OF ONCOLOGY 36: 973-982, 2010 Table III. Number of urinary proteins identified within each patient group by each mass spectrometric technique. Table IV . Protein species that were not cachexia-specific and were identified in at least 3 individual samples of any patient group of 8 (i.e. 37.5%).
-----------------------------------------------------------------------------------------------------Urinary proteins identified ------------------------------------------------------------
----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
- 
------------------------------------------------------------------------------------------------------------------------------------------------
No. of individuals excreting protein (out of 8) -------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------
Results reported as maximum number of peptides detected by MALDI-MS and LC-MS/MS within a single sample and maximum peptide percentage coverage detected by MALDI-MS within a single sample. a Difference from HC group on FE test P<0.05.
but was not cachexia-specific as it was also found in one healthy control. Myosin 18b is detected predominantly in all types of striated muscle but at much lower levels compared to class II sarcomeric myosins. It moves into the myonuclei on differentiation to possibly regulate muscle-specific genes (26) . The cytoskeletal proteins detected in cachectic urine included ·-spectrin 1 (non-erythrocytic) and nischarin. The ß spectrins I and IV were also found in several cachectic samples but were not specific. The spectrins are a family of widelydistributed filamentous cytoskeletal protein heterodimers that consist of a constant ·-chain and variable, tissue-specific ß-chains, which associate with short actin filaments to form a hexagonal mesh. They play an important role in the maintenance of plasma membrane integrity (27) . In pathological processes such as diffuse axonal injury, cleavage of ·-spectrin by calpain/caspase activity (an enzyme system hypothesized to be involved in the early stages of myofibrillar degradation) leads to membrane disruption and, ultimately, cellular death (27) , suggesting that the cachectic process may involve membrane disruption. ·-spectrin has been found to be overexpressed in intestinal-type gastric tumours (28) , but in our cohort was found primarily in samples from patients with oesophageal cancer. Nischarin binds to the cytoplasmic domain of the integrin ·5 subunit, thus inhibiting cell motility, and altering actin filament organization (29) .
Another high-molecular weight cytoskeletal protein involved in integrin function and found in a high proportion of the cachectic samples, albeit non-specifically, was talin-2. Talin is concentrated at regions of cell-substratum contact and is capable of activating integrins enabling linkage to the actin cytoskeleton (30) . It is also a substrate for the calpain system (31). Table V . Protein species that were specifically identified in at least 3 of the 8 (37.5%) cancer cachexia urine samples and which therefore represent candidate biomarkers of cachexia. --------------------------------------------------------------------------------------------------- 
Results reported as maximum number of peptides and maximum percentage coverage found by MALDI within a single sample.
a Difference from both HC and WS group on FE test P<0.05. b Difference from both HC and WS group on FE test P<0.01. Table VI . Functions of candidate biomarkers of cachexia.
- Myosin 5C Powers actin-based membrane trafficking, particularly of transferrin (49) . Expressed in many secretory and glandular tissues.
Myosin 7A Expressed in testis, kidney, lung, inner ear, retina and the ciliated epithelium of nasal mucosa. Gene mutations are responsible for Usher syndrome type 1B (50) , an autosomal recessive condition characterized by deafness and gradual vision loss.
Myosin, heavy polypeptide 7, Gene defects cause familial hypertrophic cardiomyopathy type 1 (51), myosin storage myopathy (involves type I fiber predominance and cardiac muscle, ß variant increased interstitial fat and connective tissue) (52) , and Laing early-onset distal myopathy (53) .
Myosin 9A Expressed in all mammalian tissues. Involved in control of actin cytoskeleton by negatively regulating the small G-protein Rho (54) .
Gene mutations implicated in Bardet-Biedl syndrome (autosomal recessive disorder characterized by cognitive impairment, obesity, retinitis pigmentosa, syndactyly/polydactyly, short stature, and hypogenitalism) (55).
Myosin 10
Involved in mitotic spindle function and filopodia formation (56) . Tail contains multiple pleckstrin homology domains (57) .
Nischarin
Binds to cytoplasmic domain of integrin ·5 subunit, inhibiting cell motility and altering actin filament organization (29) . Inhibits Racinduced migration and invasion of epithelial cells by affecting PAK signaling cascades (58).
·-spectrin
(non-erythrocytic)
Cleavage of ·-spectrin by calpain/caspase leads to membrane disruption and cellular death (27) . Overexpressed in some gastric tumours (28) .
Zinc finger protein 106 homolog
Unknown.
The microtubule-associated proteins found specifically in the cachectic samples included microtubule associated protein 1B (MAP1B) and microtubule actin crosslinking factor 1 (MACF1). Microtubule-associated proteins (MAPs), including MAP1B, are thought to regulate the formation and stability of microtubules via their interaction with tubulin (32) . MACF1 is a member of the plakin family of cytoskeletal linker proteins and is a structural hybrid of dystrophin (at the C-terminal) and bullous pemphigoid antigen 1 (BPAG1) (at the N-terminal) (33) . BPAG-1 is another member of the plakin family which is highly expressed in skeletal muscle (34) and which was also identified specifically in the CC group. Two-thirds of the cancer samples expressed Ig κ-light chain and/or ZAG. Ig light chains have been detected in the urine of ill patients since 1848 (so-called Bence-Jones protein).
More recently, we have demonstrated Ig κ-light chains in the urine of patients with chronic heart failure and various malignancies (35) . ZAG has been found previously in increased quantities in the urine of patients with bladder cancer (36) . Furthermore, ZAG has been postulated as the lipid mobilizing factor in cachexia (37) . However, the tumour-secreted proteolysis inducing factor (38) was not detected in any of the urine samples.
Some MS studies have suggested that the urinary proteome may contain ~1,500 species (39) . Only a third of proteins identified are described as classical circulatory plasma proteins, which are known to be relatively abundant in urine despite their retention to a large extent during the glomerular filtration process. However, other studies have demonstrated that sequential preparation of urine samples by gel filtration and protein precipitation results in low amounts of detectable protein on 2D gels (40) . These latter results are consistent with our own findings. Improvements in methodology, such as the use of storage agents (41); alternative strategies of protein precipitation (42) ; a return to 2D PAGE (43); or bioinformatics (43) may all increase the yield of potential biomarkers.
In the present study, weight loss alone was used as the definition of cachexia. We have shown previously that a 3-factor profile of cancer cachexia, incorporating weight loss, dietary intake and systemic inflammation, better defines groups with worsened prognostic outcome (44) . Future biomarker studies which incorporate more detailed definitions of cachexia will help to elucidate changes caused independently by systemic inflammation and hyponutrition.
In summary, urinary proteomics using MS techniques can identify candidate molecules for potential targeting as novel biomarkers of cachexia in GO cancer patients. Biomarker strategies targeting myofibrillar, cytoskeletal and microtubule-associated proteins within the context of future longitudinal studies of large patient numbers will be required to assess fully the changing prevalence of biomarkers within different cachectic populations.
